Acumen Pharmaceuticals (ABOS) Change in Accured Expenses (2020 - 2026)

Acumen Pharmaceuticals has reported Change in Accured Expenses for 7 years, with the latest figure at -$5.0 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 8505.0% year-over-year to -$5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.8 million (down 149.71% YoY) and the FY2025 annual result came in at $3.3 million, up 10215.62% from the prior year.
• Change in Accured Expenses slipped to -$5.0 million in Q1 2026 per ABOS's latest filing, from $2.2 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $4.9 million in Q2 2025 and troughed at -$5.0 million in Q1 2026.
• A 5-year average of $35705.9 and a median of $370000.0 in 2022 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2026: Change in Accured Expenses soared 6266.67% in 2022, then tumbled 8505.0% in 2026.
• Over 5 years, Change in Accured Expenses stood at $500000.0 in 2022, then surged by 512.2% to $3.1 million in 2023, then slumped by 50.18% to $1.5 million in 2024, then surged by 46.56% to $2.2 million in 2025, then slumped by 325.64% to -$5.0 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$5.0 million, $2.2 million, and -$3.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.